Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

OBJECTIVE: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gynecol Oncol
Главные авторы: Wade, K.N. Slaughter, Brady, M.F., Thai, T., Wang, Y., Zheng, B., Salani, R., Tewari, K.S., Gray, H.J., Bakkum-Gamez, J.N., Burger, R.A., Moore, K.N., Bookman, M.A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048388/
https://ncbi.nlm.nih.gov/pubmed/31409486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.07.020
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы